全文获取类型
收费全文 | 3334篇 |
免费 | 233篇 |
出版年
2023年 | 17篇 |
2022年 | 19篇 |
2021年 | 34篇 |
2020年 | 34篇 |
2019年 | 49篇 |
2018年 | 108篇 |
2017年 | 78篇 |
2016年 | 138篇 |
2015年 | 215篇 |
2014年 | 178篇 |
2013年 | 280篇 |
2012年 | 245篇 |
2011年 | 204篇 |
2010年 | 172篇 |
2009年 | 149篇 |
2008年 | 179篇 |
2007年 | 128篇 |
2006年 | 111篇 |
2005年 | 115篇 |
2004年 | 111篇 |
2003年 | 89篇 |
2002年 | 93篇 |
2001年 | 63篇 |
2000年 | 66篇 |
1999年 | 63篇 |
1998年 | 25篇 |
1997年 | 27篇 |
1996年 | 26篇 |
1995年 | 21篇 |
1994年 | 13篇 |
1993年 | 17篇 |
1992年 | 48篇 |
1991年 | 37篇 |
1990年 | 33篇 |
1989年 | 30篇 |
1988年 | 25篇 |
1987年 | 31篇 |
1986年 | 26篇 |
1985年 | 25篇 |
1984年 | 16篇 |
1983年 | 15篇 |
1982年 | 12篇 |
1980年 | 11篇 |
1975年 | 11篇 |
1974年 | 13篇 |
1973年 | 16篇 |
1972年 | 20篇 |
1970年 | 16篇 |
1968年 | 11篇 |
1965年 | 20篇 |
排序方式: 共有3567条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Background
With increasing computer power, simulating the dynamics of complex systems in chemistry and biology is becoming increasingly routine. The modelling of individual reactions in (bio)chemical systems involves a large number of random events that can be simulated by the stochastic simulation algorithm (SSA). The key quantity is the step size, or waiting time, τ, whose value inversely depends on the size of the propensities of the different channel reactions and which needs to be re-evaluated after every firing event. Such a discrete event simulation may be extremely expensive, in particular for stiff systems where τ can be very short due to the fast kinetics of some of the channel reactions. Several alternative methods have been put forward to increase the integration step size. The so-called τ-leap approach takes a larger step size by allowing all the reactions to fire, from a Poisson or Binomial distribution, within that step. Although the expected value for the different species in the reactive system is maintained with respect to more precise methods, the variance at steady state can suffer from large errors as τ grows. 相似文献5.
The cell cycle modulated glycoprotein GP115 is one of the major yeast proteins containing glycosylphosphatidylinositol 总被引:11,自引:0,他引:11
The cell cycle modulated protein gp115 (115 kDa, isoelectric point about 4.8-5) of Saccharomyces cerevisiae undergoes various post-translational modifications. It is N-glycosylated during its maturation along the secretory pathway where an intermediary precursor of 100 kDa (p100), dynamically related to the mature gp115 protein, is detected at the level of endoplasmic reticulum. Moreover, we have shown by the use of metabolic labeling with [35S]methionine, [3H]palmitic acid and myo-[3H]inositol combined with high resolution two-dimensional gel electrophoresis and immunoprecipitation with a specific antiserum, that gp115 is one of the major palmitate- and inositol-containing proteins in yeast. These results, and the susceptibility of gp115 to phosphatidylinositol-specific phospholipase C treatment strongly indicate that gp115 contains the glycosylphosphatidylinositol (GPI) structure as membrane anchor domain. The two-dimensional analysis of the palmitate- and inositol-labeled proteins has also allowed the characterization of other polypeptides which possibly contain a GPI structure. 相似文献
6.
7.
Daniel Rivas-Barragan Sarah Mubeen Francesc Guim Bernat Martin Hofmann-Apitius Daniel Domingo-Fernndez 《PLoS computational biology》2020,16(12)
Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats. 相似文献
8.
9.